MIBRAR® for Meniscus Tear — Regeneration Without Arthroscopy

Meniscus tear is one of the most common knee joint injuries. Menisci are cartilage cushions that absorb load and stabilize the knee. For tears, standard medicine offers arthroscopy — resection (removal) or meniscus suture. MIBRAR® allows meniscus tissue restoration without surgical intervention.

Meniscus Tear: The Regeneration Problem

The meniscus has extremely limited blood supply. Only the outer third (red zone) receives blood and is capable of self-healing. The inner two-thirds (white zone) lack blood vessels and practically cannot heal on their own.

Problems with standard treatment:

• Meniscus resection — removing the damaged part accelerates arthrosis development
• Meniscus suture — only possible in the red zone, prolonged rehabilitation
• Conservative treatment — does not restore tissue

How MIBRAR® Restores the Meniscus

The ARK® concentrate contains mesenchymal stem cells capable of differentiating into chondrocytes — meniscus cartilage cells. When injected into the knee joint:

• Stem cells migrate to the tear zone
• Growth factors stimulate formation of new cartilage tissue
• Meniscus structure is restored even in the white zone
• Joint inflammation and swelling decrease

Indications

• Partial tears of medial and lateral menisci
• Degenerative meniscus damage
• White zone tears (not suitable for suture)
• Recurrence after arthroscopy
• Meniscus damage combined with arthrosis

MIBRAR® vs Arthroscopy

Results and Cost

• Pain and locking reduction — from the first days
• Meniscus tissue restoration on MRI — 3–6 months
• Overall improvement up to 85% — by 8–16 weeks